Explore Treatments for Multifocal Motor Neuropathy (MMN)

Multifocal motor neuropathy (MMN) is a rare, progressive, autoimmune disease of the nerves controlling muscle movement. It typically develops gradually, leading to asymmetrical weakness in the limbs, most often without numbness, tingling, or pain. Patients may also experience fasciculations, or small involuntary muscle twitches beneath the skin. MMN is not life-threatening and does not affect life expectancy; however, it is a long-term condition without remission. While there is no cure, treatment can slow disease progression and significantly improve function. Many patients respond well to therapy and experience only mild symptoms over extended periods. Despite this, MMN can lead to notable disability. Weakness in the hands may impair the ability to work or perform daily tasks, while foot drop can make walking or standing difficult. In more advanced cases, some individuals may require mobility aids such as canes or walkers.

Treatments Offered by CSI

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma is rigorously processed and purified to ensure product safety and integrity. Intravenous immunoglobulin (IVIG) contains antibodies that provide broad protection against a wide range of bacteria and viruses. It is administered intravenously and is primarily used to treat three categories of conditions: primary immunodeficiency diseases, autoimmune disorders, and certain neurological conditions.  

  • Alyglo 10% 
  • Asceniv 10% 
  • Bivigam 10% 
  • Gammagard S/D 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Gammaplex 5% 
  • Gammaplex 10% 
  • Octagam 5% 
  • Octagam 10% 
  • Panzyga 10% 
  • Privigen 10% 
  • Yimmugo 10% 

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma undergoes rigorous processing and purification to ensure the highest standards of safety and product integrity. Subcutaneous immunoglobulin (SCIG) contains antibodies that offer broad protection against a wide range of bacteria and viruses. It is administered under the skin (subcutaneously) and is primarily used to treat primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy (CIDP). SCIG is also being studied in clinical trials for use in additional conditions. 

  • Cutaquig 16.5%  
  • Cuvitru 20% 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Hizentra 20% 
  • HyQvia 10% (facilitated SCIG)  
  • Xembify 20%